€0.67
Your prediction
Atara Biotherapeutics Inc. Stock
Pros and Cons of Atara Biotherapeutics Inc. in the next few years
Pros
Cons
Performance of Atara Biotherapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Atara Biotherapeutics Inc. | 2.450% | 3.642% | 5.730% | -72.599% | 31.480% | -94.255% | - |
| Ardelyx Inc. | 0.130% | -5.482% | -15.972% | 32.578% | 3.218% | -12.905% | - |
| Salarius Pharmaceuticals Inc. | 0.950% | -0.935% | -18.462% | -68.120% | -23.604% | -98.261% | -99.994% |
| Brainstorm Cell | 1.170% | -0.896% | -1.485% | -81.710% | 114.440% | -80.717% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.From initial impressions, it appears that Atara Biotherapeutics, a biopharmaceutical company engaged in the development of therapeutics for patients with autoimmune diseases and cancer, is facing some significant financial challenges from a holistic point of view.
Starting with the balance sheet, it is disconcerting to see the company's total liabilities surpass its total assets significantly, indicating negative equity in the period represented by the balance sheet of 31st March 2023. It suggests the firm may be reliant on debt and potential future capital raises to finance its operations. Furthermore, the trajectory of total assets declining with each passing year is a cause for concern. For example, total assets have decreased from approximately $588 million in 2020 to $302 million by 2023. Company's inventory amounts and net receivables also appear to be reducing year-on-year, which might indicate problems with inventory management and receivables collection.
The cash flow statements deepen the concerns as they showcase a consistent net income loss with each passing year. One of the evident cash flow drawbacks is negative operating cash flow pointing to operational inefficiencies.
